Psychopharmacology and Psychiatry Updates Standard vs. High Doses: Rethinking Bipolar Maintenance Treatment
Sep 28, 2025
Kristin Raj, psychiatry clinician and educator specializing in bipolar disorder treatment. She reviews Finnish real-world data comparing standard and high medication doses. Key topics: why standard doses often link to lower relapse rates, aripiprazole’s strong protection at low/standard doses, quetiapine’s poor long-term performance, lithium’s benefits, and safety signals with higher antipsychotic doses.
AI Snips
Chapters
Transcript
Episode notes
Patient Case That Frames The Question
- Sarah presented six months after her first manic episode on olanzapine 15 mg and lithium 900 mg with 25 lb weight gain and cognitive fog.
- This clinical vignette frames the central question: can doses be lowered after stabilization to reduce side effects without increasing relapse risk.
Standard Doses Often Best For Relapse Prevention
- Finnish nationwide data over a decade found standard doses of many antipsychotics and mood stabilizers minimized psychiatric hospitalizations.
- Drugs showing this pattern included olanzapine, risperidone, valproate, lamotrigine, and moderate-dose carbamazepine (~400 mg).
Aripiprazole Stands Out For Maintenance
- Aripiprazole showed the lowest relapse risk among antipsychotics at low and standard doses despite limited efficacy in bipolar depression.
- This suggests aripiprazole may be especially useful for broad relapse prevention in maintenance phases.